Gleevec Related Clinical Trials
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) [Active, not recruiting]
Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma [Terminated]
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma [Active, not recruiting]
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia [Completed]
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer [Active, not recruiting]
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients [Completed]
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma [Active, not recruiting]
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate [Completed]
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer [Completed]
Effect of Antacids on Gleevec® in Healthy Volunteers [Completed]
Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. [Active, not recruiting]
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) [Active, not recruiting]
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia [Active, not recruiting]
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC [Terminated]
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer [Active, not recruiting]
Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery [Active, not recruiting]
Therapy of Early Chronic Phase CML With Gleevec
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes [Completed]
Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) [Completed]
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib [Completed]
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) [Completed]
A Study of Imatinib 400 Mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis. [Completed]
Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP [Completed]
Glivec Phase II Pediatric Study [Terminated]
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia [Completed]
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Oblimersen Plus Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Active, not recruiting]
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma [Active, not recruiting]
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C [No longer recruiting]
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer [Recruiting]
Imatinib Mesylate in Treating Patients With Myelofibrosis [Active, not recruiting]
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate [No longer recruiting]
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia [Active, not recruiting]
Imatinib in Dermatofibrosarcoma Protuberans (DFSP) [Active, not recruiting]
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevecâ„¢ [Terminated]
Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors [Recruiting]
Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer [Completed]
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer [Completed]
Imatinib Mesylate in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Recruiting]
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia [No longer recruiting]
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia [Completed]
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Completed]
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor [No longer recruiting]
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib [Active, not recruiting]
Imatinib Mesylate in Treating Patients With Metastatic Melanoma [Suspended]
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer [Completed]
Adjuvant Imatinib in High-Risk GIST With c-Kit Mutation [Recruiting]
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Carcinosarcoma [No longer recruiting]
Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer [Completed]
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor [No longer recruiting]
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [No longer recruiting]
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases [Completed]
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response [Not yet recruiting]
Study of BMS-354825 in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib [Completed]
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma [No longer recruiting]
Role of Glivec in Patients With Tumor Cells Positive for c-Kit or PDGFR; a Multi Center Study. [No longer recruiting]
Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Completed]
Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer [No longer recruiting]
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer [Recruiting]
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Recruiting]
Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer [No longer recruiting]
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia [Recruiting]
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Recruiting]
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG [Recruiting]
Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Breast Cancer Patients [Recruiting]
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy [Recruiting]
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Active, not recruiting]
Study of Temzolomide and Gleevec in Advanced Melanoma [Recruiting]
Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients [Recruiting]
Gleevec Study for Patients With Ovarian Cancer [Recruiting]
Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate [Recruiting]
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST [Recruiting]
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG [Recruiting]
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma [Recruiting]
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) [Recruiting]
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma [Recruiting]
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia [Recruiting]
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma [Recruiting]
Imatinib Mesylate in Treating Patients With Myelofibrosis [Recruiting]
Imatinib Mesylate, Busulfan, Fludarabine, and ATG for CML Patients [Recruiting]
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) [Active, not recruiting]
Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers [Recruiting]
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) [Recruiting]
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing c-Kit Gene [No longer recruiting]
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) [Active, not recruiting]
Imatinib Mesylate, Interferon Alfa, and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia [Recruiting]
Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor [No longer recruiting]
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) [Recruiting]
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer [No longer recruiting]
Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers [Not yet recruiting]
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma [Active, not recruiting]
Ph II Imatinib Mesylate + Hydroxyurea in Treatment for Pts w Recurrent/Progressive Meningioma [Recruiting]
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery [Recruiting]
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma [No longer recruiting]
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma [Recruiting]
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor [Recruiting]
|
